Therefore, targeting the p53-MDM2 interaction to reactivate p53 has emerged as a promising new cancer therapeutic strategy [11,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46]. Here, MDM2 is linked to cancer.